Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Agios Pharmaceuticals, Astex Pharmaceuticals, Inc, Bristol Myers Squibb and Takeda Oncology.

New Horizons in the Management of Myelodysplastic Syndromes: Exploring Advancements from Low- to High-Risk Disease

Release Date: September 3, 2020
Expiration Date: September 3, 2021

Activity Overview

Myelodysplastic syndromes (MDS) comprise a heterogeneous group of disorders of the blood-forming stem cells in the bone marrow and results in lower than normal numbers of one or more types of blood cells. A rapidly evolving treatment landscape and changes to prognostic scoring systems have created a practice gap for healthcare providers treating patients with MDS.

This archived live webcast features a panel of experts in the field discussing optimum ways to classify and risk stratify patients with MDS, reviewing important clinical trial data evaluating newer and emerging treatment options for MDS, and outlining strategies to individualize therapy for patients with this condition, including those with high-risk and low-risk MDS, as well as elderly patients.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Agios Pharmaceuticals, Astex Pharmaceuticals, Inc, Bristol Myers Squibb and Takeda Oncology.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.


Target Audience

This educational activity is directed toward hematologists, medical oncologists, nurse practitioners, nurses, and fellows who treat patients with myelodysplastic syndromes (MDS). Physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of MDS will be invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Review available tools for MDS classification and risk stratification, based on morphological, clinical, and cytogenetic criteria
  • Outline strategies to individualize therapy in MDS based on risk stratification and patient comorbidities
  • Apply recent clinical trial findings to real-world practice for the management of MDS
  • Summarize data from recent clinical trials evaluating efficacy and safety of novel therapies to treat MDS from low- to high- risk disease

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Chair

Guillermo Garcia-Manero, MD
Guillermo Garcia-Manero, MD
Professor Chief, Section of Myelodysplastic Syndromes Deputy Chair, Translational Research Department of Leukemia The University of Texas MD Anderson Cancer Center Houston, TX

Disclosures: Grant/Research Support: AbbVie, Amphivena Therapeutics, Astex Pharmaceuticals, Celgene/Bristol Myers Squibb, H3 Biomedicine, Helsinn Advanced Synthesis SA, Merck, Novartis, Onconova Therapeutics, Consultant: Astex Pharmaceuticals, Bristol Myers Squibb, Helsinn Advanced Synthesis SA

Faculty

Amy E. DeZern, MD, MHS
Amy E. DeZern, MD, MHS
Associate Professor of Oncology and Medicine
Division of Hematologic Malignancies
The Johns Hopkins University School of Medicine
Baltimore, MD

Disclosures: Consultant: Celgene/Bristol Myers Squibb

David P. Steensma, MD
David P. Steensma, MD
Edward P. Evans Chair in MDS Research
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School

Disclosures: Grant/Research Support: Aprea Therapeutics, H3 Biosciences, Consultant: Celgene/Bristol Myers Squibb, Novartis, Onconova Therapeutics, PharmaEssentia, Takeda

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
  12345
6789101112
13141516171819
20212223242526
27282930
Filter By